Business Wire

Dimension Data and NTT Communications Join Forces to Create a Single ‘Cloud Powerhouse’ and Drive Innovation


Dimension Data, the global technology solutions and services provider, and NTT Communications, the ICT solutions and international communications business within NTT Group, will create a single ‘cloud powerhouse’ by bringing together their cloud infrastructure-as-a-service (IaaS) capabilities under the management of NTT Communications to deliver transformative, cloud-based solutions and innovation to clients of both organizations around the world.

This press release features multimedia. View the full release here:

Dimension Data and NTT Communications employ some of the most highly-skilled, sought-after cloud experts in the market. Bringing together these experts under the management of NTT Communications means the combined capabilities will have the power to drive innovation into the market and deliver the services that today’s organizations demand.

Both companies will retain their existing strategic partnerships under the new structure.

“Enterprises have an increasing need for hybrid IT to accelerate their digital transformation. Working together to enhance our cloud and value added services, combined with our industry leading networking, global data center assets and security capabilities, both Dimension Data and NTT Communications will offer clients a more compelling hybrid IT value proposition,” said Tsunehisa Okuno, Senior Vice President, Head of Global Business, NTT Holdings. “NTT’s extensive R&D investments will also enhance the range of services available to clients.”

Dimension Data Group Chief Executive Officer, Jason Goodall said: “Combining our cloud IaaS assets provides enterprises on their hybrid IT journey with a unique combination of services and expertise, on a global basis. We’ll deliver services at-scale and provide a level of innovation not currently available in the managed cloud-based hybrid IT solutions space.”

Katsumi Nakata, Senior Executive Vice President, NTT Communications said: “We’re excited that our augmented capabilities and broadened footprint will take us to the next level in global cloud IaaS platform, coupled with one of the largest software-defined network services that connect over 190 countries worldwide, more than 140 global data centres, and the world’s leading Tier 1 IP network. We are confident that we will continue to deliver superior results and contribute significantly to the success of both our clients and our cloud business.”

Clients will benefit from the new hybrid IT solutions that offer greater visibility, automation, management and governance. Other benefits include:

  • Secure and trusted global environment with public, private and hybrid cloud offerings protected by advanced networking, security features and third party certifications to meet compliance, security and company policies.
  • Consistent computing environment, programmable interfaces and automated delivery model across public and private clouds including bare metal servers, to promote agility and reduce operational costs.
  • Consumption-based billing model for private cloud to optimize commercial benefits even under tight private cloud requirements.
  • Integration with world-leading WAN and global data centers by software defined technologies to achieve flexible allocation of IT resources.
  • Single pane of glass through the cloud management platform for visualizing all the hybrid IT resources.
  • Ability to drive innovation within an open ecosystem to enable clients to leverage innovation of open-source community, vendor offerings and partners.

Leslie Rosenberg, Research Director, IDC said “NTT Communications and Dimension Data continue to demonstrate their collaboration and synergistic relationship with the announcement of a new combined cloud capability. Combining IaaS capabilities provides customers with enhanced global scale and hybrid IT capabilities. The synergy allows each company to play to their strengths – the broad reach of NTT Communications’ network and data centers coupled with Dimension Data’s technology expertise and consulting capabilities to help enable customers to achieve global scale and accelerate their hybrid IT and digital transformation initiatives.”

About Dimension Data

Dimension Data uses the power of technology to help organisations achieve great things in the digital era. As a member of the NTT Group, we accelerate our clients’ ambitions through digital infrastructure, customer experience, hybrid cloud, digital workplace, and cybersecurity. With a turnover of USD 8 billion, offices in 48 countries, and 28,000 employees, we deliver wherever our clients are, at every stage of their technology journey. We’re proud to be the Official Technology Partner of Amaury Sport Organisation, which owns the Tour de France, and the title partner of the cycling team, Team Dimension Data for Qhubeka. Visit us at

About NTT Communications

NTT Communications provides consultancy, architecture, security, cloud and managed services to optimize the information and communications technology (ICT) environments of enterprises. These offerings are backed by the company’s worldwide infrastructure, including the leading global tier-1 IP network, the Arcstar Universal One™ VPN network reaching over 190 countries/regions, and over 140 secure data centres worldwide.

Contact information

Dimension Data Holdings plc
Hilary King, +2782 414 9623
Global PR Manager
NTT Communications Corporation
Masaki Nomoto, +81-3-6700-4010
Senior Manager, PR Office

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round23.3.2018 10:00Tiedote

SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, repre

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme